PHOENIX: QL1706 plus chemo and bevacizumab in high PD-L1, driver-mutant non-squamous NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Phase II trial evaluating a quadruple therapy consisting of QL1706 (a PD-1/CTLA-4 bispecific antibody), bevacizumab, and platinum-based chemotherapy in adults with locally advanced or metastatic NSCLC carrying actionable driver mutations and PD-L1 expression ≥50%. The study uses historical chemotherapy controls to gauge whether the treatment increases the objective response rate, with secondary aims including progression-free and overall survival. It is an open-label, multi-cohort design without a concurrent control group, conducted in China with two sites. Eligible patients must have progressed after at least one TKI, a ECOG 0-1, measurable disease, and specific driver mutations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

The study will enroll adult patients (aged 18-75 years) with histologically confirmed locally advanced or metastatic NSCLC (AJCC 9th Edition, Stage IIIB-IVB), and harbor confirmed actionable driver mutations for which targeted therapies are available; these mutations are stratified as follows: EGFR (19del, L858R); ALK, ROS1, RET fusions; KRAS G12C; BRAF V600; and HER2 exon 20 insertions. Patients must have disease progression following at least one line of TKI therapy and a 2-week washout period is required for prior TKI therapy or chemotherapy. Prior immunotherapy is not permitted. PD-L1 tumor proportion score (TPS) ≥ 50%, as confirmed by central laboratory testing using the 22C3 or SP263 clone on fresh or archival tumor tissue (collected within 2 years). Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, and presence of at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Exclusion Criteria:

* Prior treatment with QL1706 or other investigational PD-1/PD-L1/CTLA-4 antibodies, unless allowed by the protocol.
* Untreated or symptomatic central nervous system (CNS) metastases. Participants with previously treated, stable, and asymptomatic CNS metastases off steroids for at least 2 weeks before first dose may be eligible.
* History of severe allergic reactions or hypersensitivity to monoclonal antibodies, platinum agents, pemetrexed, bevacizumab, or any excipients of the study drugs.
* Clinically significant cardiovascular disease, including but not limited to:
* Uncontrolled hypertension despite optimal medical management
* New York Heart Association (NYHA) class III or IV heart failure
* Unstable angina, myocardial infarction, or stroke within 6 months prior to enrollment
* Significant arrhythmias requiring anti-arrhythmic therapy
* Active or history of autoimmune disease that has required systemic treatment in the past 2 years (e.g., with disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for conditions such as vitiligo, resolved childhood asthma/atopy, or hypothyroidism on stable replacement therapy.
* Active infection requiring systemic therapy, including known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection, unless well controlled according to protocol-defined criteria.
* Significant hemoptysis (e.g., ≥ 2.5 mL of bright red blood) within 3 months prior to enrollment or any evidence of high-risk bleeding or coagulation disorder that would contraindicate bevacizumab.
* Major surgery within 4 weeks before first dose of study treatment or anticipated need for major surgery during the study.
* Pregnant or breastfeeding women.
* Any other serious medical condition, uncontrolled intercurrent illness, psychiatric illness, or social circumstance that, in the opinion of the investigator, would compromise the participant's safety, interfere with study evaluations, or preclude informed consent.

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong,China, China Recruiting
• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong,China, China Recruiting

Study contacts

• Study coordinator: Hao Sun, Doctor
• Email: sunhao@gdph.org.cn
• Phone: +86 16620178852

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• IB-FOLFIRI for BRAF V600E metastatic colorectal cancer

  This trial tests whether adding the immune drugs Iparomlimab and Tuvonralimab to bevacizumab and FOLFIRI helps adults with BRAF V600E metastatic colorectal cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07150247

• HAIC plus iparomlimab or tuvonralimab with bevacizumab, followed by SBRT for advanced liver cancer with portal vein involvement or limited metastases

  This trial will test whether giving hepatic artery infusion chemotherapy with an immune checkpoint antibody (iparomlimab or tuvonralimab) plus bevacizumab, followed by focused stereotactic radiation, helps people with advanced hepatocellular carcinoma that involves the portal vein or has a small number of metastases.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07062055

• Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer

  In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07882888

• Iparomlimab/Tuvonralimab with nab-paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer

  This trial tests whether adding Iparomlimab/Tuvonralimab to nab-paclitaxel and cisplatin before surgery can shrink locally advanced cervical cancer and safely be given to adult women.

  Recruiting Phase 2 Xijing Hospital · Xi'an, Shaanxi · NCT07876154

• Neoadjuvant immunotherapy plus Nab-P-SOX for locally advanced gastric/GEJ cancer

  This phase 2, single-arm study tests a pre-surgery treatment that combines a PD-1/CTLA-4 bispecific antibody with nab-paclitaxel, oxaliplatin, and S-1 in adults with HER2-negative, locally advanced gastric or GEJ cancer.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07867392

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.